Table 1. Baseline Characteristics of the Subgroups Receiving Ipragliflozin Alone or With Metformin.
| Ipragliflozin alone (n = 9) | Ipragliflozin with metformin (n = 11) | P value | |
|---|---|---|---|
| Women | 3 | 6 | 0.369 |
| Age (years) | 53 ± 10 | 51 ± 7 | 0.626 |
| Body weight (kg) | 82.5 ± 7.9 | 81.9 ± 13.9 | 0.915 |
| Body mass index (kg/m2) | 29 ± 2.3 | 30.2 ± 3.8 | 0.416 |
| Duration of diabetes (years) | 3 (1 - 6) | 8 (6.5 - 12) | 0.079 |
| Fasting plasma glucose (mg/dL) | 161 ± 17 | 181 ± 50 | 0.288 |
| Hemoglobin A1c (%) | 8.0 ± 1.4 | 8.4 ± 1.3 | 0.502 |
| Systolic blood pressure (mm Hg) | 139 ± 11 | 130 ± 17 | 0.207 |
| Diastolic blood pressure (mm Hg) | 82 ± 12 | 80 ± 15 | 0.767 |
| eGFR (mL/min/1.73 m2) | 88 ± 11 | 92 ± 11 | 0.437 |
| LDL-C (mg/dL) | 127 ± 22 | 105 ± 27 | 0.057 |
| HDL-C (mg/dL) | 50 ± 11 | 46 ± 7 | 0.373 |
| Triglycerides (mg/dL) | 118 ± 51 | 114 ± 48 | 0.055 |
| Lactate (mmol/L) | 1.1 ± 0.4 | 1.6 ± 0.4 | 0.027 |
| Medications (n) | |||
| Sulfonylurea | 3 | 4 | |
| Thiazolidinedione | 1 | 2 | |
| α-Glucosidase inhibitor | 0 | 4 | |
| DPP-4 inhibitor | 3 | 4 | |
| Insulin | 4 | 4 | |
| GLP-1 receptor agonist | 0 | 4 |
Data are expressed as the mean ± standard deviation for continuous variables or as the median (IQR). Categorical variables are expressed as numbers. eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; IQR: interquartile range.